Arrowhead Pharmaceuticals has released compelling data from two phase 3 clinical trials, positioning the company as a serious contender in the severe hypertriglyceridemia treatment space. The results come less than a month
More
Summit Therapeutics has released updated overall survival data from its phase 3 HARMONi trial as the FDA moves toward a landmark decision on ivonescimab. The new analysis, based on a data cut-off
More
Law firm Colombo and Hurd has secured an EB-2 National Interest Waiver green card for an anti-money laundering and compliance professional from Ecuador. The client, who specialises in financial crime risk management,
More
The U.S. Court of Appeals for the Second Circuit has ruled that employees must show an adverse employment decision was motivated by their need for religious accommodation to establish a prima facie
More
The Justice Department entered a Manhattan courtroom on Thursday armed with grand jury subpoenas targeting New York Times reporters and left without them after a bruising hearing. The subpoenas were directed at
More
Kim Kardashian has launched a new campaign for her brand UPDATE, leaning into her well-publicised struggles with the bar exam as a marketing tool. Rather than hiding from the joke, Kardashian has
More
UK markets opened on a mixed note on 24 July 2026, as investors weighed a series of major corporate developments alongside ongoing geopolitical and macroeconomic pressures. The FTSE 100 slipped marginally by
More
Johnson & Johnson remains one of the most closely watched stocks on Wall Street, with retail and institutional investors alike tracking every major analyst and media recommendation. Jim Cramer, the well-known host
More
Estate agents are warning UK property sellers that overpricing their homes could leave them waiting significantly longer to complete a sale. New research from Savills reveals that sellers who overprice and are
More
Samsung Biologics (KRX: 207940) has announced plans to acquire Swiss peptide manufacturer PolyPeptide in a deal worth approximately $1.8 billion, marking a landmark moment for South Korean biopharma. The transaction is described
More